František Horn1, Michal Petrík2, Dana Dúbravová2, Jarmila Hornová3, Katrína Brennerová3, Vladimír Bzduch3. 1. Department of Pediatric Surgery, Faculty of Medicine, Comenius University, National Institute of Children Diseases, Limbova 2643/1, 83340, Bratislava, Slovak Republic. frantisek.horn@gmail.com. 2. Department of Pediatric Surgery, Faculty of Medicine, Comenius University, National Institute of Children Diseases, Limbova 2643/1, 83340, Bratislava, Slovak Republic. 3. Department of Pediatrics, Faculty of Medicine, Comenius University, National Institute of Children Diseases, Bratislava, Slovak Republic.
Abstract
PURPOSE: Intrathecal baclofen administration is commonly used in the treatment of children's spasticity. In general, candidates for baclofen pump are patients with spastic form of cerebral palsy. Intrathecal baclofen in the treatment of spasticity due to a metabolic disorder is rarely reported. METHODS: Authors report on an 11-year-old boy with mucopolysaccharidosis type II (Hunter syndrome) with progressive stiffness and contractures followed by profound loss of joint movement range and tiptoe walking pattern. Patient was indicated for baclofen test with subsequent pump insertion and continuous intrathecal baclofen administration. RESULTS: Postoperatively, patient was gradually set to current baclofen dose of 250 μg/day. At mentioned dose, we observed not only increased active and passive range of movements and facilitation in fine motor skills, but also better walking pattern. CONCLUSIONS: Despite intrathecal baclofen administration in patients with spasticity related to mucopolysaccharidosis type II is not widely reported, we consider it as feasible treatment. To emphasize, enzyme replacement therapy is the primary treatment, and improvement is attributed to both enzyme substitution and intrathecal baclofen therapy.
PURPOSE: Intrathecal baclofen administration is commonly used in the treatment of children's spasticity. In general, candidates for baclofen pump are patients with spastic form of cerebral palsy. Intrathecal baclofen in the treatment of spasticity due to a metabolic disorder is rarely reported. METHODS: Authors report on an 11-year-old boy with mucopolysaccharidosis type II (Hunter syndrome) with progressive stiffness and contractures followed by profound loss of joint movement range and tiptoe walking pattern. Patient was indicated for baclofen test with subsequent pump insertion and continuous intrathecal baclofen administration. RESULTS: Postoperatively, patient was gradually set to current baclofen dose of 250 μg/day. At mentioned dose, we observed not only increased active and passive range of movements and facilitation in fine motor skills, but also better walking pattern. CONCLUSIONS: Despite intrathecal baclofen administration in patients with spasticity related to mucopolysaccharidosis type II is not widely reported, we consider it as feasible treatment. To emphasize, enzyme replacement therapy is the primary treatment, and improvement is attributed to both enzyme substitution and intrathecal baclofen therapy.
Authors: Agnieszka Jurecka; Zita Krumina; Zbigniew Żuber; Agnieszka Różdżyńska-Świątkowska; Anna Kłoska; Barbara Czartoryska; Anna Tylki-Szymańska Journal: Am J Med Genet A Date: 2012-01-13 Impact factor: 2.802
Authors: Harshal Ingale; Ismail Ughratdar; Samiul Muquit; Ahmad A Moussa; Michael H Vloeberghs Journal: Childs Nerv Syst Date: 2015-11-09 Impact factor: 1.475
Authors: Joseph Muenzer; Christian J Hendriksz; Zheng Fan; Suresh Vijayaraghavan; Victor Perry; Saikat Santra; Guirish A Solanki; Mary Ann Mascelli; Luying Pan; Nan Wang; Kenneth Sciarappa; Ann J Barbier Journal: Genet Med Date: 2015-04-02 Impact factor: 8.822
Authors: Young Bae Sohn; Sung Yoon Cho; Sung Won Park; Su Jin Kim; Ah-Ra Ko; Eun-Kyung Kwon; Sun Ju Han; Dong-Kyu Jin Journal: Orphanet J Rare Dis Date: 2013-03-18 Impact factor: 4.123
Authors: Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe Journal: Orphanet J Rare Dis Date: 2020-05-14 Impact factor: 4.123